Swiss National Bank
AQST icon

Swiss National Bank’s Aquestive Therapeutics AQST Stock Holding History

Swiss National Bank’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-202,700
Closed -$1.31M – 2304
2025
Q4 		$1.31M Buy
+202,700
New +$1.26M ﹤0.01% 2057

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Swiss National Bank's AQST Position: Q1 2026 in Review

Swiss National Bank sold out of Aquestive Therapeutics (AQST) in Q1 2026, closing a stake of 202,700 shares — an estimated $1.31M sold.

Swiss National Bank first reported a position in AQST in Q4 2025 and held it in 1 quarter. The position peaked at $1.31M in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Swiss National Bank reported no remaining Aquestive Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Swiss National Bank sold 202,700 Aquestive Therapeutics shares in Q1 2026, an estimated $1.31M.
  • Swiss National Bank first reported a position in Aquestive Therapeutics in Q4 2025 and held it in 1 quarter.
  • Swiss National Bank's Aquestive Therapeutics position peaked at $1.31M in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.